Assessment of Current Biomarker Testing Practices for Common Solid Cancers in Precision Oncology in the Community Setting
Withdrawn
HSV G207 With a Single Radiation Dose in Children With Recurrent High-Grade Glioma
Phase 2 Withdrawn
SupCare
Phase NA Withdrawn
Incidence of HPV Infection and HPV-Associated Disease in Screening Indian Men Who Have Sex With HIV-Positive Men
Withdrawn
AMBER
Phase 2 Withdrawn
BOUNCE
Phase 2 Withdrawn
Cost of Cancer Risk Management in Women at Elevated Genetic Risk for Ovarian Cancer Who Participated on GOG-0199
Withdrawn
Biomarkers in Samples From Patients With Endometrial Cancer
Withdrawn
Testing the Addition of an Investigational Drug, Xevinapant, to Usual Radiation Therapy Plus Cisplatin/Carboplatin for Patients With Head and Neck Cancer
Phase 2 Withdrawn
Testing the Use of Targeted Treatment for RET Positive Advanced Non-small Cell Lung Cancer
Phase 2 Withdrawn
Chemo-free BRCA-targeted Neoadjuvant Strategy
Phase 2 Withdrawn
A Study of the Drug IMGN632 in Children With Leukemia That Has Come Back After Treatment or is Difficult to Treat
Phase 1/2 Withdrawn
Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced or Refractory Solid Tumors
Phase NA Withdrawn
Androgen Ablation Therapy With or Without Vaccine Therapy in Treating Patients With Prostate Cancer
Phase 2 Withdrawn
C-Met Inhibitor AMG 337, Oxaliplatin, Leucovorin Calcium, and Fluorouracil in Treating Patients With Advanced Stomach or Esophageal Cancer
Phase 1/2 Withdrawn
Fludeoxyglucose F-18 PET/CT in Predicting Response to Chemotherapy in Patients With Stage IIIA Non-small Cell Lung Cancer That Can Be Removed by Surgery
Phase 2 Withdrawn
A Single Arm Phase II Study to Evaluate Treatment With Gevokizumab in Patients With Stage II/III Colon Cancer Who Are ctDNA-positive After Curative Surgery and Adjuvant Chemotherapy
Phase 2 Withdrawn
Testing the Addition of Paclitaxel and Carboplatin Given After Standard Chemotherapy and Radiation for Cervical Cancer in HIV-positive Women
Phase 2 Withdrawn
PAMICC
Phase 2 Withdrawn
SOLUTION
Phase 2 Withdrawn
Safety and Efficacy Study of Neratinib and Cetuximab to Treat Patients With Quadruple Wild-Type Metastatic Colorectal Cancer
Phase 1/2 Withdrawn
PROMPT
Phase 2 Withdrawn
ADHERE
Phase 3 Withdrawn
H11
Phase 3 Withdrawn
CAST
Phase 1 Withdrawn
Testing of TAK228 (MLN0128, Sapanisertib) Plus Docetaxel to the Usual Standard of Care for Advanced Squamous Cell Lung Cancer (A Lung-MAP Treatment Trial)
Phase 2 Withdrawn
Imetelstat Given Intravenously Alone and With Standard 13-Cis-Retinoic Acid in Children With Neuroblastoma
Phase 1 Withdrawn
ARN-509
Phase 3 Withdrawn
FACPAR
Withdrawn
Vaccine Therapy and OPT-821 or OPT-821 Alone in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer in Complete Remission
Phase 3 Withdrawn
DYNAMIC
Phase 2 Withdrawn
TELEFIRST
Phase 3 Withdrawn
PERIDENO
Phase 2 Withdrawn
Trastuzumab Beyond Progression in HER2 Positive Metastatic Gastric Cancer
Phase 2 Withdrawn
SPECTAbrain
Withdrawn
TRADITIONS
Phase 3 Withdrawn
Biomarkers in Blood Samples From Young Patients With Newly Diagnosed Brain Tumors Undergoing Standard Radiation Therapy and Chemotherapy
Phase NA Withdrawn
Palifermin in Preventing Oral Mucositis Caused by Chemotherapy and/or Radiation Therapy in Young Patients Undergoing Stem Cell Transplant
Phase 2 Withdrawn
Studying Body Mass Index in Younger Patients Who Are Receiving Treatment for High-Risk Acute Lymphoblastic Leukemia
Withdrawn
Biomarker Study in Samples From Patients With Malignant Rhabdoid Tumor of the Kidney or Atypical Teratoid Rhabdoid Tumor
Withdrawn
Studying Biomarkers in Samples From Younger Patients With Kidney Cancer
Withdrawn
Imetelstat Sodium in Treating Younger Patients With Relapsed or Refractory Solid Tumors
Phase 2 Withdrawn
SPECTAmel: Screening Patients With Melanoma Tumors for Efficient Clinical Trial Access
Withdrawn
Donor Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia in Remission
Phase 2 Withdrawn
Oregovomab With or Without Cyclophosphamide in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Responded to Second-Line Chemotherapy
Phase NA Withdrawn
Breast Cancer Risk in Women Who Are BRCA1/BRCA2 Mutation Carriers
Withdrawn
BOS3
Phase 2/3 Withdrawn
MEGAN
Phase 2 Withdrawn
S0716 Vandetanib and Docetaxel in Treating Patients With Advanced Solid Tumors
Phase 1 Withdrawn
Lenvatinib in Second Line Endometrial Carcinoma
Phase 2 Withdrawn